FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma By Ogkologos - March 25, 2026 47 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the MajesTEC-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Tarlatamab Transdermal Oestradiol Patches Non-inferior to LHRH Agonists Regarding Metastasis-Free Survival in Patients with Locally Advanced Prostate Cancer EMA Recommends Extension of Indications for Selpercatinib MOST POPULAR Deputy Spends His Days Off Teaching Life Skills To Young Boys... December 26, 2021 EMA Recommends Extension of Therapeutic Indications for Pembrolizumab to Include Neoadjuvant... March 13, 2024 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? August 20, 2024 Long-Term Follow-Up Confirms a Sustained Reduction in Deaths from Prostate Cancer... November 4, 2025 Load more HOT NEWS How Anxiety Impacts People With Cancer and How to Cope Self Destruction ‘A significant step forwards’ – treating patients with advanced biliary tract... HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy...
